- Trial Phase
- Phase 3 (pivotal NOVA-2 ongoing); Phase 2 (NOVA-1) completed and published
- Time to Market
- Unknown — earliest realistic US approval roughly 2028-2029 assuming a positive Phase 3 readout in H1 2027, an NDA filing thereafter, and a standard FDA review; LB-102 is a Phase 3 drug, not yet filed.
- Why 7/10
- The next hard, dated catalyst is the topline readout of the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia, guided to H1 2027 (accelerated from H2 2027) with a pre-NDA FDA meeting planned for H2 2027 — a binary on the company's lead, near-single-asset program roughly 5-10 months out, hence 7 rather than 8 (readout not confirmed within ~6 months).
Watch for NOVA-2 enrollment-completion and any further timing updates — the H1 2027 topline is the defining binary for this stock. Note the stock (~$47) already trades above the mean analyst price target (~$45.88), and FINRA short interest of ~4.75M shares (~16.6% of estimated shares outstanding, ~12.8 days to cover as of 7/31/26) could amplify the move in either direction when data lands. The July 2026 $150M placement (≈15% dilution) is done, so watch for additional financing only if the readout slips.
Price Chart
Executive Summary
LB-102 (N-methylamisulpride) is LB Pharmaceuticals' lead and essentially only asset: a once-daily oral D2/D3/5-HT7 antagonist for schizophrenia, built on the decades-old amisulpride chemistry with a tweak meant to improve brain penetration. Positive Phase 2 (NOVA-1) data were published in JAMA Psychiatry in April 2026, and the pivotal Phase 3 NOVA-2 trial is enrolling fast enough that management accelerated the topline readout to H1 2027, with a pre-NDA FDA meeting planned for H2 2027. The company IPO'd in September 2025, raised ~$100M then ~$150M in 2026 private placements (≈15% dilution in July), and guided cash runway into Q2 2029. Institutional money (BlackRock, JPMorgan, Vanguard, Goldman) accumulated heavily in Q2 2026 and a 10% owner (Deep Track) bought ~$10M of pre-funded warrants — but the stock has roughly doubled in 6 months, trades above the mean analyst target, and still carries a binary Phase 3 readout that has released no efficacy data yet.
How It Works
LB-102 is a once-daily oral pill that blocks dopamine D2/D3 receptors (the classic target for antipsychotic drugs) plus a serotonin 5-HT7 receptor. It is a close chemical cousin of amisulpride, an antipsychotic used in Europe for decades, with a single added methyl group that reportedly helps the drug cross the blood-brain barrier, allowing lower, once-daily dosing — a potential "first benzamide" in the US market.
Trial Status
Phase 2 NOVA-1 in acute schizophrenia was positive and published in JAMA Psychiatry (April 22, 2026). The pivotal Phase 3 NOVA-2 trial (~460 patients, 25 US sites, randomized double-blind placebo-controlled) is enrolling faster than expected, with topline now expected H1 2027. A 52-week open-label safety study (NOVA-3) is also running, plus Phase 2 ILLUMINATE-1 in bipolar 1 depression (ongoing) and a Phase 2 adjunctive-MDD study (planned).
The Two-Sided Case
Upcoming Catalysts
- Phase 3 NOVA-2 topline data in schizophrenia — H1 2027 (accelerated from H2 2027)
- Pre-NDA meeting with FDA — H2 2027
- Phase 2 ILLUMINATE-1 (bipolar 1 depression) readout — timing to be announced
- NOVA-2 enrollment-completion announcements and any further timeline acceleration
- Quarterly earnings/corporate updates (next: Q3 2026) and pipeline-expansion news
Source Filing
The SecBot filing or press-release report that triggered this drug report:
LB Pharmaceuticals Inc Press Release LBRX ·Originating report